AUS
NZ
UK
CA
USA
IND
_05_20_2025_03_31_02_914728.jpg)
Highlights
- ResMed and Netwealth show strong recent performance momentum
- ResMed’s valuation trends below its historical average
- Both companies stand out within the broader S&P/ASX300 landscape
The new year has brought renewed attention to two notable companies in the S&P/ASX300 index: ResMed CDI (ASX:RMD) and Netwealth Group Ltd (ASX:NWL). Both have shown promising signs in 2025, with ResMed's share price rising 5.1% since January, and Netwealth trading nearly 57% above its 52-week low. These trends have drawn attention from those exploring opportunities among listed companies on the ASX.
ResMed, headquartered in San Diego but with Australian roots, is known for its innovative contributions to sleep and respiratory care. The company operates two main divisions: Sleep and Respiratory Care and Software as a Service (SaaS). Its CPAP machines for treating obstructive sleep apnea (OSA) are widely recognized in global healthcare markets. Additionally, the SaaS arm offers digital solutions to streamline the management of out-of-hospital and durable medical equipment needs.
With a workforce of over 10,000 and operations in more than 140 countries, ResMed has carved out a strong international presence. Its ability to integrate hardware with cloud-based data platforms enables better health outcomes while driving down overall costs—a key focus in today’s healthcare landscape.
From a valuation perspective, ResMed currently holds a price-to-sales (P/S) ratio of 5.28x, compared to its five-year average of 8.70x. This suggests that the share price is trading below historical valuation levels, especially considering its consistent revenue growth over recent years. While no single metric tells the whole story, the current P/S ratio offers an initial lens into the company’s broader position.
On the other hand, Netwealth continues to strengthen its platform-based wealth management model. With over 140,000 account holders and more than $88 billion in funds under administration as of 2024, the company has grown into one of the major players in Australia's digital investment platform space. Its appeal lies in its user-friendly interface and consolidated dashboard, enabling smooth management of diverse financial tasks from performance tracking to reporting.
Netwealth's scale advantage and digital ease-of-use contribute to its recognition among tech-enabled financial service firms within the S&P/ASX300.
For those examining the wider landscape of Australian shares, both ResMed and Netwealth represent sectors that intersect technology and essential services—two pillars gaining momentum within the ASX300 index in recent times. While they don’t fall directly under traditional ASX dividend stocks, their growth narratives and sector relevance place them firmly on the radar.
As the market progresses through 2025, these companies offer insights into the evolving interplay between innovation, healthcare, and financial services across Australia’s equity markets.
